{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:00:05Z","timestamp":1787313605942,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejca.2020.12.014","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T15:47:45Z","timestamp":1611848865000},"page":"230-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin\u00a0alpha4 therapy"],"prefix":"10.1016","volume":"145","author":[{"given":"Sarah","family":"Basin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Cauquil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.12.014_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Haugh","year":"2014","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2020.12.014_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.12.014_bib3","first-page":"267","article-title":"Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: a case report","volume":"10","author":"Niki","year":"2018","journal-title":"Mol Clin Onc"},{"issue":"1","key":"10.1016\/j.ejca.2020.12.014_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse drug event report database","volume":"145","author":"Sato","year":"2019","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.ejca.2020.12.014_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.12.014_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.12.014_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/CCO.0000000000000222","article-title":"Update on neurological paraneoplastic syndromes","volume":"27","author":"H\u00f6ftberger","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2020.12.014_bib8","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis","volume":"73","author":"Fang","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejca.2020.12.014_bib9","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1172\/JCI117519","article-title":"The pathophysiologic role of alpha 4 integrins in\u00a0vivo","volume":"94","author":"Lobb","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2020.12.014_bib10","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:45Z","timestamp":1760733105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920314398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":10,"alternative-id":["S0959804920314398"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin\u00a0alpha4 therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}